DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Monomethyl auristatin E
Monomethyl auristatin E
Download Product Insert (PDF)
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’S Lymphomas Version 2.2015
Complete Remission of Refractory, Ulcerated, Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma Following Brentuximab Vedotin Therapy
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma
Adcetris® (Brentuximab Injection for Intravenous Use – Seattle Genetics, Inc.)
Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines
Download of These Slides, Please Direct Your Browser to the Following Web Address
An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
Brentuximab Vedotin: Axonal Microtubule&Rsquo;S Apollyon
Trial Watch: Antibody–Drug Conjugate Shows Efficacy in Lymphoma
Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1 Lawrence J
ADCETRIS® (Brentuximab Vedotin) for Injection, for Intravenous Use • Peripheral Neuropathy: Monitor Patients for Neuropathy and Institute Initial U.S
Celldex Announces Publication of Glembatumumab Vedotin Phase 1/2 Studies in the Journal of Clinical Oncology
Reference ID: 3359579
Resistance to Antibody–Drug Conjugates Sara García-Alonso1, Alberto Ocana~ 2, and Atanasio Pandiella1
(POLIVY®) Antibody–Drug Conjugate in Sprague Dawley Rats
A Prostate-Specific Membrane Antigen (PSMA)
Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin Brentuximab Vedotine Dramatik Yanıtlı Kutanöz Anaplastik Büyük Hücreli Lenfoma
Top View
Celldex Announces Completion of Enrollment in Phase 2B Study of Glembatumumab Vedotin in Triple Negative Breast Cancer
Polivy (Polatuzumab Vedotin-Piiq) – New Orphan Drug Approval
Glembatumumab Vedotin for Patients with Metastatic, Gpnmb Overexpressing, Triple-Negative Breast Cancer (“METRIC”): a Randomized Multicenter Study ✉ Linda T
Tumor Associated Macrophages Can Contribute to Antitumor Activity Through Fcγr-Mediated Processing of Antibody-Drug Conjugates
Hydrophilic Monomethyl Auristatin E Derivatives As Novel Candidates for the Design of Antibody-Drug Conjugates
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
Precision Chemo-Radiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability
Anti-CD22 and Anti-CD79B Antibody Drug Conjugates Are Active in Different Molecular Diffuse Large B-Cell Lymphoma Subtypes
Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-Doligobody)
Monomethyl Auristatin E, a Potent Cytotoxic Payload for Development of Antibody-Drug Conjugates Against Breast Cancer
Theranostics a Novel Anti-DR5 Antibody-Drug Conjugate Possesses
Antibody-Drug Conjugates: the New Frontier of Chemotherapy
Free MMAE Toxin Quantitation by Triple Quadrupole in Antibody Drug Conjugate Analysis
Improving the Serum Stability of Site-Specific Antibody Conjugates
Cutaneous T-Cell Lymphoma: Systemic Therapy
Tunable Cytotoxic Aptamer–Drug Conjugates for the Treatment of Prostate Cancer
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
FDA Approved for Any PTCL Subtype with CD30 Expression (≥1%)2
Monomethyl Auristatin E-Conjugated Anti-EGFR Antibody Inhibits The
DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Current Status of Marine-Derived Compounds As Warheads in Anti-Tumor Drug Candidates
Oncology Fact Sheet Nr.5 Update
Development and Properties of Valine-Alanine Based Antibody-Drug Conjugates with Monomethyl Auristatin E As the Potent Payload
Phase II Trial of the Glycoprotein Non-Metastatic B-Targeted Antibody
Improving the Potency of Auristatin Cancer Drugs by Virtual Structure Modifications
Interbiotech Monomethyl Auristatin E
761121Orig1s000